Rosetta to Offer $35M in Public Offering, Receives NYS Approval for Lung Cancer Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics on Monday filed a preliminary prospectus with the US Securities and Exchange Commission for a public offering of common stock aimed at raising up to $35 million.

The company also announced that its miRview lung assay has received conditional approval by the New York State Department of Health.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.